Rating Change
JP Morgan analysts reiterated a Overweight rating on Lexeo Therapeutics, Inc. Common Stock (NASDAQ:LXEO) on June 25, 2026.
reiterateNASDAQ:LXEO
JP Morgan Reiterates Overweight Rating on Lexeo Therapeutics, Inc. Common Stock (LXEO)
Rating Change JP Morgan analysts reiterated a Overweight rating on Lexeo Therapeutics, Inc. Common Stock (NASDAQ:LXEO) on June 25, 2026. Market Context Lexeo Therapeutics, Inc.
Market Context
Lexeo Therapeutics, Inc. Common Stock operates in the Healthcare sector. The stock currently trades at $4.70 with a market capitalization of $715.6M.
Analyst coverage from JP Morgan provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for Lexeo Therapeutics, Inc. Common Stock.
Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.
Recent Analyst Activity for Lexeo Therapeutics, Inc. Common Stock
Among the 10 most recent ratings: 10 Buy, 0 Hold, 0 Sell.
| Date | Firm | Rating | Price Target |
|---|---|---|---|
| Jun 25, 2026 | JP Morgan | Overweight | N/A |
| May 11, 2026 | Chardan Capital | Buy | N/A |
| Jan 13, 2026 | Chardan Capital | Buy | N/A |
| Jan 13, 2026 | HC Wainwright & Co. | Buy | N/A |
| Dec 18, 2025 | Raymond James | Strong Buy | N/A |
Related Tools: Analyst Ratings Dashboard | View LXEO Stock Page
Frequently Asked Questions
What does a Overweight rating mean for LXEO?
A Overweight rating from JP Morgan reflects the analyst's outlook on Lexeo Therapeutics, Inc. Common Stock (NASDAQ:LXEO). Analyst ratings are one factor investors consider alongside earnings, valuation, and sector trends.
Where can I find more analyst ratings?
Browse recent upgrades and downgrades on our Analyst Ratings Dashboard or the LXEO forecast page.